IDEF Educational Series VTAMA tapinarof cream, 1% as a Novel Topical Therapy for Adult Plaque Psori

Join us for our next International Dermatology Foundation Educational Series Webinar: VTAMA (tapinarof) cream, 1% as a Novel Topical Therapy for Adult Plaque Psoriasis. Take a deep dive into the VTAMA (tapinarof) cream data and learn more about this once-daily, steroid-free option for your adult plaque psoriasis patients. Important Safety Information Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. ---------------------------------- Moderator: Leon Kircik, MD, FAAD President, International Dermatology Education Foundation Clinical Professor of Dermatology Icahn School of Medicine at Mount Sinai, New York, NY Indiana University Medical Center, Indianapolis, IN Medical Director Physicians Skin Care, PLLC, Louisville, KY DermResearch, PLLC, Louisville, KY Skin Sciences, PLLC, Louisville, KY Speakers: Mona Shahriari, MD Assistant Clinical Professor of Dermatology, Yale University School of Medicine Associate Director of Clinical Trials, CCD Research Senior Editor, Journal of Psoriasis and Psoriatic Arthritis Central Connecticut Dermatology